Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms

被引:18
|
作者
Shimomura, Yutaro [1 ]
Kikuchi, Yuhei [1 ]
Suzuki, Takefumi [2 ]
Uchida, Hiroyuki [1 ]
Mimura, Masaru [1 ]
Takeuchi, Hiroyoshi [1 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[2] Univ Yamanashi, Fac Med, Dept Neuropsychiat, Yamanashi, Japan
关键词
Algorithms; Antipsychotics; Guidelines; Non-response; Schizophrenia; Treatment resistance; NAIVE 1ST-EPISODE SCHIZOPHRENIA; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED-TRIAL; CLOZAPINE; AUGMENTATION; METAANALYSIS; MANAGEMENT; DRUGS; SCALE; RISPERIDONE;
D O I
10.1016/j.schres.2021.07.040
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: To summarize the current state of knowledge on antipsychotic treatment strategies for the acute phase and treatment resistance in schizophrenia, we conducted a systematic review of guidelines and algorithms. Methods: We conducted a systematic literature search to identify clinical guidelines and algorithms on this topic using MEDLINE and Embase. We extracted information on recommendations for antipsychotic treatment strategies, including those for non-response (i.e., increasing antipsychotic dose and switching to another antipsychotic) and treatment resistance. Results: We identified a total of 17 guidelines/algorithms in various countries that were published after 2011. With respect to antipsychotic dose, most of the guidelines (N = 10/11) agreed starting with a low dose or the lowest licensed/effective dose and then titrating the dose upwards. Regarding antipsychotic treatment strategies for non-response, all of the guidelines (N = 9/9) recommended increasing antipsychotic dose towards the upper end of its approved dose range. Five guidelines suggested for increasing beyond the therapeutic dose range in exceptional cases, while overall 10 guidelines including them were negative about such strategy. The vast majority of guidelines (N = 16/17) recommended switching to another antipsychotic for non-response; however, some guidelines mentioned the lack of evidence for these strategies other than the use of clozapine. All the guidelines (N = 17/17) endorsed initiating clozapine after failure to respond to 2 different antipsychotics. Four guidelines endorsed an early use of clozapine, yet as the third antipsychotic. Conclusion: The currently available guidelines and algorithms recommended increasing antipsychotic dose and switching to another antipsychotic, particularly clozapine for treatment-resistant schizophrenia, during the acute phase of schizophrenia for non-response.
引用
收藏
页码:142 / 155
页数:14
相关论文
共 50 条
  • [1] Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms
    Shimomura, Yutaro
    Kikuchi, Yuhei
    Suzuki, Takefumi
    Uchida, Hiroyuki
    Mimura, Masaru
    Takeuchi, Hiroyoshi
    SCHIZOPHRENIA RESEARCH, 2020, 215 : 8 - 16
  • [2] Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms
    Takeuchi, Hiroyoshi
    Suzuki, Takefumi
    Uchida, Hiroyuki
    Watanabe, Koichiro
    Mimura, Masaru
    SCHIZOPHRENIA RESEARCH, 2012, 134 (2-3) : 219 - 225
  • [3] Critical review of antipsychotic polypharmacy in the treatment of schizophrenia
    Fleischhacker, W. Wolfgang
    Uchida, Hiroyuki
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 (07) : 1083 - 1093
  • [4] Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia
    Hatta, Kotaro
    Ito, Hiroto
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2014, 12 (01) : 1 - 7
  • [5] Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis
    Pagsberg, Anne Katrine
    Tarp, Simon
    Glintborg, Dorte
    Stenstrom, Anne Dorte
    Fink-Jensen, Anders
    Correll, Christoph Ulrich
    Christensen, Robin
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (03) : 191 - 202
  • [6] The heterogeneity of antipsychotic response in the treatment of schizophrenia
    Case, M.
    Stauffer, V. L.
    Ascher-Svanum, H.
    Conley, R.
    Kapur, S.
    Kane, J. M.
    Kollack-Walker, S.
    Jacob, J.
    Kinon, B. J.
    PSYCHOLOGICAL MEDICINE, 2011, 41 (06) : 1291 - 1300
  • [7] Resting-state functional connectivity in treatment response and resistance in schizophrenia: A systematic review
    Chan, Nathan K.
    Kim, Julia
    Shah, Parita
    Brown, Eric E.
    Plitman, Eric
    Carravaggio, Fernando
    Iwata, Yusuke
    Gerretsen, Philip
    Graff-Guerrero, Ariel
    SCHIZOPHRENIA RESEARCH, 2019, 211 : 10 - 20
  • [8] The effect of lifetime adversities on resistance to antipsychotic treatment in schizophrenia patients
    Hassan, Ahmed N.
    De Luca, Vincenzo
    SCHIZOPHRENIA RESEARCH, 2015, 161 (2-3) : 496 - 500
  • [9] Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review
    Roiz-Santianez, Roberto
    Suarez-Pinilla, Paula
    Crespo-Facorro, Benedicto
    CURRENT NEUROPHARMACOLOGY, 2015, 13 (04) : 422 - 434
  • [10] Heterogeneity and Efficacy of Antipsychotic Treatment for Schizophrenia With or Without Treatment Resistance: A Meta-Analysis
    Mizuno, Yuya
    McCutcheon, Robert
    Brugger, Stefan
    Howes, Oliver
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 176 - 177